Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Pecs
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05100719CT.gov The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) | — | Not Yet Recruiting | — | — | — |
NCT01145586CT.gov A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lactose Intolerance
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lactase (this asset) | University of Pecs | P3 | BB · 64 |
| Rp-G28 | Ritter Pharmaceuticals, Inc. | P3 | A |
| Streptococcus Thermophilus Dsm 24731 | Société des Produits Nestlé (SPN) | N/A | D |
| Lac Vaccinum | Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement | N/A | D |
| Ged (Ppargamma Modulator) | University Hospital, Lille | N/A | D |
| A2 beta-casein | Purdue University | N/A | D |
| Alverine | University of Pecs | N/A | D |
| Bifidobacterium Longum | Société des Produits Nestlé (SPN) | N/A | D |
| Simethicone | University of Pecs | N/A | D |
+1 more in the Lactose Intolerance cohort
Other indications for Lactase
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Irritable Bowel Syndrome | — | N/A | D · 30 |
| Lactose Intolerance Adult Type | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lactase in Lactose Intolerance. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lactase-lactose-intolerance
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →